Grifols, S.A. Stock

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:29:58 2024-04-22 am EDT 5-day change 1st Jan Change
8.294 EUR -0.62% Intraday chart for Grifols, S.A. -3.50% -46.44%
Sales 2024 * 7.09B 7.55B Sales 2025 * 7.63B 8.12B Capitalization 5.05B 5.38B
Net income 2024 * 489M 520M Net income 2025 * 732M 779M EV / Sales 2024 * 2 x
Net Debt 2024 * 9.12B 9.7B Net Debt 2025 * 8.33B 8.87B EV / Sales 2025 * 1.75 x
P/E ratio 2024 *
10.6 x
P/E ratio 2025 *
7.49 x
Employees 23,744
Yield 2024 *
-
Yield 2025 *
2.86%
Free-Float 89.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.56%
1 week-3.50%
Current month-0.72%
1 month+4.60%
3 months-6.10%
6 months-19.47%
Current year-46.44%
More quotes
1 week
8.21
Extreme 8.206
8.94
1 month
7.71
Extreme 7.71
9.67
Current year
6.36
Extreme 6.362
15.63
1 year
6.36
Extreme 6.362
15.92
3 years
6.36
Extreme 6.362
25.94
5 years
6.36
Extreme 6.362
34.31
10 years
6.36
Extreme 6.362
34.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 Feb. 05
Director of Finance/CFO 67 06-12-31
Chairman 65 06-04-04
Members of the board TitleAgeSince
Chairman 65 06-04-04
Director/Board Member 68 00-04-12
Director/Board Member 61 01-07-26
More insiders
Date Price Change Volume
24-04-22 8.294 -0.62% 1 462 424
24-04-19 8.346 -3.16% 3,288,156
24-04-18 8.618 -2.45% 1,907,396
24-04-17 8.834 +1.59% 2,493,069
24-04-16 8.696 +1.38% 2,095,982

Delayed Quote BME, April 22, 2024 at 11:13 am EDT

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
8.346 EUR
Average target price
18.03 EUR
Spread / Average Target
+116.06%
Consensus